The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis

Abstract

SB-705498 12 mg for 8 days did not alleviate the allergen-induced symptoms of AR, or provide additional relief of symptoms when in combination with FP. Despite engagement of the TRPV1 receptor there was no translation to clinical efficacy, suggesting redundancy in symptom pathways.